Hepatitis C Drugs A Good Fit For Outcomes-Based Contracts, McClellan Tells Insurers
Executive Summary
The former CMS and FDA head suggested at an AHIP conference that performance-based payments could help pave the way for a new “pricing model” for specialty drugs in the U.S.